Angiotensin II receptor blockers in congestive heart failure

Cardiology in Review

Volumn 14, Issue 1, 2006, Pages 26-34

  Eisenberg, Mark J ^a,b   Gioia, Laura C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Quebec Foundation for Health Research   (Canada)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitor; Clinical trials; Congestive heart failure

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEALTH PROGRAM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MEDICAL SOCIETY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33644874142     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000182409.91935.85     Document Type: Review

References (62)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Available at: http://www.americanheart.org/downloadable/heart/ 1105390918119HDSStats2005Update.pdf. Accessed July 22, 2005.
2. American Heart Association. Heart Disease and Stroke Statistics - 2001 Update. Available at: http://216.185.102.50/statistics/othercvd.html. Accessed March 2003.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
6. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
7. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
8. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101-2113.
9. Jamali AH, Tang WH, Khot UN, et al. The role of angiotensin receptor blockers in the management of chronic heart failure. Arch Intern Med. 2001;161:667-672.
10. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334:1649-1654.
11. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol. 1999;39:547-559.
12. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89:3A-9A.
13. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
14. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
15. Petrie MC, Padmanabhan N, McDonald JE, et al. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol. 2001;37:1056-1061.
16. Weber MA. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens. 1999;12:189S-194S.
17. Kirch W, Horn B, Schweizer J. Comparison of angiotensin II receptor antagonists. Eur J Clin Invest. 2001;31:698-706.
18. US Food and Drug Administration. Benicar product monograph NDA 21-286. April 25, 2002. Available at: http://www.fda.gov/cder/foi/label/2002/21286lbl. pdf. Accessed June 15, 2005.
19. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
20. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-107.
21. Chan P, Tomlinson B, Huang TY, et al. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol. 1997;37:253-257.
22. Lacourciere Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens. 1994;12:1387-1393.
23. Sharma D, Buyse M, Pitt B, et al. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. Am J Cardiol. 2000;85:187-192.
24. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99:1926-1935.
25. Sato M, Engelman RM, Otani H, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation. 2000;102:346-351.
26. Pitt B. Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn? Am J Hypertens. 2002;15:22S-27S.
27. Byyny RL. Antihypertensive efficacy of the angiotensin II AT-1 receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group. Blood Press Suppl. 1996;14:1147-1151.
28. Kloner RA, Weinberger M, Pool JL, et al. Comparative effects of Candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol. 2001;87:727-731.
29. ABC Investigators. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. Heart Dis. 2000;2:392-396.
30. McInnes GT, O'Kane KP, Istad H, et al. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000;14:263-269.
31. Oparil S, Levine JH, Zuschke CA, et al. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol. 1999;84:289-293.
32. Pool JL, Glazer R, Chiang YT, et al. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999;13:275-281.
33. Cifkova R, Peleska J, Hradec J, et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998;12:563-567.
34. Mimran A, Ruilope L, Kerwin L, et al. A randomized, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998;12:203-208.
35. Stumpe KO, Haworth D, Hoglund C, et al. Comparison of the angiotension II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press. 1998;7:31-37.
36. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602-1609.
37. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26:438-445.
38. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation. 1995;91:691-697.
39. Weber M. Clinical safety and tolerability of losartan. Clin Ther. 1997;19:604-616.
40. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol. 1997;30:983-991.
41. Mazayev VP, Fomina IG, Kazakov EN, et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol. 1998;65:239-246.
42. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999;99:990-992.
43. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J. 1999;20:1182-1190.
44. Riegger GA, Bouzo H, Petr P, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure. Circulation. 1999;100:2224-2230.
45. Baruch L, Anand I, Cohen IS, et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation. 1999;99:2658-2664.
46. Warner JG Jr, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol. 1999;33:1567-1572.
47. Havranek EP, Thomas I, Smith WB, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol. 1999;33:1174-1181.
48. Parker AB, Azevedo ER, Baird MG, et al. ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. Am Heart J. 1999;138:843-848.
49. Guazzi M, Palermo P, Pontone G, et al. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol. 1999;84:1038-1043.
50. Cowley AJ, Wiens BL, Segal R, et al. Randomised comparison of losartan vs captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. Qual Life Res. 2000;9:377-384.
51. Tonkon M, Awan N, Niazi I, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract. 2000;54:11-18.
52. Murdoch DR, McDonagh TA, Farmer R, et al. ADEPT: addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001;141:800-807.
53. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
54. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 1999;100:1056-1064.
55. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
56. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
57. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
58. Granger CB, McMurray JJ, Yusuf S, et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
59. Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.
60. Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
61. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet. 2002;306:752-760.
62. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.